» Articles » PMID: 36494713

Preventative Practices and Effects of the COVID-19 Pandemic on Caregivers of Children with Pediatric Pulmonary Hypertension

Overview
Publisher Biomed Central
Specialty Public Health
Date 2022 Dec 9
PMID 36494713
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Pulmonary hypertension (PH) is a serious and life-threatening disease characterized by elevated mean arterial pressure and pulmonary vascular resistance. COVID-19 may exacerbate PH, as evidenced by higher mortality rates among those with PH. The objective of this study was to understand the unique burdens that the COVID-19 pandemic has placed upon families of children living with PH.

Methods: Participants were recruited online through the "Families of children with pulmonary hypertension" Facebook group and asked to complete a survey about their experiences during the COVID-19 pandemic.

Results: A total of 139 parents/caregivers of children living with PH completed the online survey. Almost all (85.6%) of parents/caregivers had received the COVID-19 vaccine, though only 59.7% reported a willingness to vaccinate their child with PH against COVID-19. Over 75% of parents/caregivers felt that they practiced preventative measures (e.g., wearing a facemask, social distancing, and avoiding gatherings) more than those in the community where they live. They also reported several hardships related to caring for their child with PH during the pandemic such as financial duress, loss of work, and affording treatment costs.

Conclusions: These findings indicate that parents/caregivers of children at higher risk for COVID-19 complications may be more willing to act on clinical recommendations themselves as proxy for protecting those at high risk. The economic, emotional and social impacts of COVID-19 are significantly greater for high-risk individuals.

Citing Articles

Quantifying side effects and caregiver burdens of pediatric pulmonary hypertension therapies.

Nelson E, Cook E, Nelson S, Brown R, Pierce M, Seelos A BMC Pediatr. 2023; 23(1):43.

PMID: 36698086 PMC: 9875396. DOI: 10.1186/s12887-023-03860-2.

References
1.
Peacock A, Murphy N, McMurray J, Caballero L, Stewart S . An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007; 30(1):104-9. DOI: 10.1183/09031936.00092306. View

2.
Gaine S, Rubin L . Primary pulmonary hypertension. Lancet. 1998; 352(9129):719-25. DOI: 10.1016/S0140-6736(98)02111-4. View

3.
Cantrell M, Lupinacci P . Methodological issues in online data collection. J Adv Nurs. 2007; 60(5):544-9. DOI: 10.1111/j.1365-2648.2007.04448.x. View

4.
Ling Y, Johnson M, Kiely D, Condliffe R, Elliot C, Gibbs J . Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med. 2012; 186(8):790-6. DOI: 10.1164/rccm.201203-0383OC. View

5.
Frost A, Badesch D, Barst R, Benza R, Elliott C, Farber H . The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2010; 139(1):128-37. DOI: 10.1378/chest.10-0075. View